Neurophet AQUA (V3.1)

The Neurophet AQUA (V3.1) system is an automated MR imaging post-processing software designed for the precise volumetric quantification and visualization of brain structures and lesions, enhancing the identification of abnormalities through integrated T2 FLAIR analysis. Its performance is rigorously validated against expert manual segmentations and a reference device, ensuring accurate and reproducible morphometric reports for clinical use.

Neurophet, Inc.'s Neurophet AQUA (V3.1) system has received a determination of substantial equivalence, classifying it as a Class II medical image management and processing system. This regulatory approval permits the company to market the device, which is subject to general controls and other applicable regulations governing quality systems, labeling, and adverse event reporting. The system is designed to provide automated post-processing of MR images. Neurophet AQUA (V3.1) specializes in the labeling, visualization, and volumetric quantification of segmentable brain structures and lesions, generating morphometric reports that compare measured volumes to age and gender-matched reference percentile data. A significant enhancement in this version is the integration of quantitative analysis for T2 FLAIR images, which improves the identification of brain abnormalities. The device's accuracy and reproducibility were rigorously validated through comprehensive testing against expert manual segmentations and a reference device, using diverse clinical and demographic datasets.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical conditions or patient populations is Neurophet AQUA (V3.1) most beneficial for diagnosing or monitoring, particularly with the T2 FLAIR integration?; How does the system's performance, particularly in terms of sensitivity and specificity for lesion detection, compare to established clinical standards or other similar automated systems in real-world settings?; What are the potential limitations or sources of error in the automated segmentation and volumetric quantification, especially concerning image quality variations or atypical brain anatomies?; Are there plans for further updates to Neurophet AQUA, such as incorporating additional imaging sequences (e.g., DTI, perfusion) or expanding its utility for other neurological conditions?; How does the comparison to age and gender-matched reference percentile data aid in clinical decision-making, and what is the demographic diversity and size of the reference database?